Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual, Tomas, Apellániz-Ruiz, María, Pernaut, Cristina, Cueto-Felgueroso, Cecilia, Villalba, Pablo, Álvarez, Carlos, Manso, Luis, Inglada-Pérez, Lucia, Robledo, Mercedes, Rodríguez-Antona, Cristina, Ciruelos, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519037/
https://www.ncbi.nlm.nih.gov/pubmed/28727815
http://dx.doi.org/10.1371/journal.pone.0180192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519037/
https://www.ncbi.nlm.nih.gov/pubmed/28727815
http://dx.doi.org/10.1371/journal.pone.0180192

Ejemplares similares